Main Conference Day 1: Tuesday, January 26, 2010

8:35 Welcome Address And Chairperson’s Opening Remarks

The Current Anti-Infective Drug Discovery & Development Market Landscape

8:45 Opening Keynote: Industry Overview - The Current Shape Of Anti-Bacterial R&D

• Knowing which direction the anti-bacterials market is heading
• Examining the emergence & challenges of novel drug classes
• Evaluating narrow vs broad spectrum
• Bridging the funding gap
• Discussing new strategies and creative partnerships for improving success

David J. Payne
PhD, Vice President Antibacterial DPU, Infectious Diseases Center of Excellence in Drug Discovery
GlaxoSmithKline

9:30 Paradise Lost, Paradise Found? - The Changing Fortunes Of Antibacterial Drug Development And Commercialization

• Changing Environment & Dynamics of Antibacterial Development and Commercialization
• Displaying the steps to become sustainable reinforcement as a Global Category Leader (GCL) within the infectious diseases drug discovery arena
• Current trends – evolving resistance and decreasing investment levels
• Understanding current antibacterial market dynamics
• Examining future pipelines and their implications

Chris Thomson
PhD, Director, Licensing & Business Development
Astellas Pharma Europe Ltd

Novel Anti-Infective Drug Development Approaches

11:00 Formulating An Appropriate Novel Anti-Infective Drug Development Pipeline

• Formulating a senior management buy-in for your organization to fight against withdrawing from multidrug-resistant bacteria development pipelines
• Strategically working with a partnering organization or spin-off who focus specifically within certain anti-infective areas
• Effectively forging a strategic biotech alliance, for optimizing the development pipeline
• Successful drug development can shoulder most of the responsibility for developing the next generation of anti-infectives
• Seeking to build product portfolios within specific anti-infective therapeutic areas (case study)

Nkechi Azie
MD, Senior Medical Director
Astellas Pharma US

11:45 Improving Antibacterial Discovery: A Critical Path For Minimizing Attrition Due To CV Liabilities

• Acute functional cardiovascular toxicity: a special consideration for antibiotic drug discovery
• Understanding QT liability and Torsade de Pointes (TdP) during lead optimization
• Role of hERG inhibition in QT prolongation and Torsade de Points
• Beyong hERG assays for predicting TdP risk: Rabbit Ventricular Wedge assay
• Lead optimization for antibacterial programs with respect to acute functional cardiovascular toxicity

Neil D. Pearson
PhD, Director Medicinal Chemistry, Antibacterial DPU, Infectious Diseases Center of Excellence in Drug Discovery
GlaxoSmithKline

Novel Therapeutic Approaches and Areas

1:30 Discovering Novel Candidates Affective Against Superbugs (Torezolid [TR-701] Case Study)

• Discussing effective results for the treatment of severe complicated skin and skin structure infections caused by gram-positive bacteria
• Displaying positive results especially against drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA)
• Describing a randomized Phase 2, double-blind, dose-ranging study conducted at eight centers in the United States
• Examining overall cure rates for severe abscesses, cellulitis, and wound infections which were 96%, 97%, and 90%, respectively
• Evaluating a second-generation oral and IV antibacterial drug in the oxazolidinone class with activity against drug-resistant, grampositive bacterial pathogens, including those resistant to linezolid

John Finn
PhD, Chief Scientific Officer
Trius Therapeutics

2:15 Targeting Superbugs: New Bicyclolides Effective Against MRSA And VRE

• Discussing recent advances in macrolide research against MRSA and VRE
• Identifying targeted product profiles
• Uncovering the history and discovery of new anti-MRSA macrolides
• Overcoming bacterial resistance
• In vitro and In vivo activities

Ly Tam Phan
PhD, Senior Director Medicinal Chemistry
Enanta Pharmaceuticals Inc.

3:00 Towards A Novel Regimen For The Treatment Of TB: An Update On PNU-100480

• Examining the current state of TB therapy and the challenge of increasing medical need
• Displaying updates on ongoing clinical studies with PNU-100480
• Discussing the current status of the global TB drug candidate portfolio
• Evaluating novel strategies for identifying promising new TB regimens

Paul Miller
PhD, Executive Director, Anti-Bacterials
Pfizer

4:30 Sustained Release Of Nitric Oxide From Hybrid Nanoparticle Platform: A Novel Therapeutic Strategy For Cutaneous Infections

• The role of nitric oxide in host immunity/defense
• Nanotechnology as a delivery system for topical therapeutics
• Novel hybrid nitric oxide releasing nanoparticles
• Efficacy of nitric oxide releasing nanoparticles against Methicillin Resistant Staphylococcus aureus wound and soft tissue infections
• Future directions and organisms to be targeted

Adam Friedman
MD, Chief Resident, Department of Medicine, Division of Dermatology
Albert Einstein College of Medicine

The Global Growth of Infectious Diseases

5:15 Emerging Market Countries And Infectious Disease Needs

• Effectively addressing the global threat of new and reemerging infectious diseases
• Inducing international cooperation in identifying, controlling, and preventing these diseases
• Examining some basic problems that global campaigns against emerging infectious diseases face in applying international law to facilitate international cooperation
• Discussing international solutions to emerging infections
• Identifying common elements of global emerging-disease control plans
• Evaluating alternative international legal strategies to revising the International Health Regulations

Baoming Jiang
DVM, PhD, Gastroenteritis & Respiratory Viruses Lab Branch
Centers for Disease Control and Prevention

6:00 Chairperson’s Closing Remarks And End Of Day One

[ Register Now ]